Savvy Advisors Inc. Purchases 22,138 Shares of Novo Nordisk A/S $NVO

Savvy Advisors Inc. grew its position in Novo Nordisk A/S (NYSE:NVO) by 83.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,824 shares of the company’s stock after acquiring an additional 22,138 shares during the period. Savvy Advisors Inc.’s holdings in Novo Nordisk A/S were worth $2,709,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. GK Wealth Management LLC lifted its stake in Novo Nordisk A/S by 26.4% in the 3rd quarter. GK Wealth Management LLC now owns 6,086 shares of the company’s stock valued at $338,000 after purchasing an additional 1,270 shares during the last quarter. Caprock Group LLC bought a new stake in Novo Nordisk A/S in the third quarter valued at approximately $2,784,000. Seaview Investment Managers LLC acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $7,696,000. Stratos Wealth Partners LTD. lifted its position in shares of Novo Nordisk A/S by 199.7% in the third quarter. Stratos Wealth Partners LTD. now owns 36,527 shares of the company’s stock valued at $2,027,000 after buying an additional 24,340 shares during the last quarter. Finally, Stratos Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 17.1% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 4,600 shares of the company’s stock worth $255,000 after acquiring an additional 672 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.7%

NYSE NVO opened at $48.77 on Thursday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a market cap of $217.78 billion, a price-to-earnings ratio of 14.06 and a beta of 0.67. The company has a 50 day moving average of $53.69 and a 200-day moving average of $53.39. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 52.74%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on NVO shares. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. HSBC reiterated a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. CICC Research started coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Finally, Citigroup assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $56.07.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo plans to roll out Wegovy vials, expanding how the obesity pill can be administered and potentially improving uptake and supply flexibility. Article Title
• Positive Sentiment: CEO Mike Doustdar highlighted a potential ~15 million-patient opportunity if Medicare expands obesity coverage, a material long-term demand tailwind for GLP‑1 drugs. Article Title
• Positive Sentiment: Market protection: Hims & Hers pulled compounded semaglutide after regulatory pressure and a patent suit, which can help defend Novo’s pricing and market share for branded semaglutide products. Article Title
• Positive Sentiment: A study finds many Wegovy pill users are new to GLP‑1 therapy, suggesting the treatments are expanding the addressable market rather than just shifting existing users — a demand-positive signal. Article Title
• Neutral Sentiment: Board members and executives reported recent trading in NVO shares — routine disclosure that can attract attention but isn’t a direct operational signal. Article Title
• Neutral Sentiment: Industry context: coverage comparing Eli Lilly and Novo highlights a duopoly in a market that could approach $100B — competition remains intense but also validates large market opportunity. Article Title
• Negative Sentiment: Regulatory pressure: the FDA flagged a Novo TV ad for the Wegovy pill as misleading, and reporting highlights mounting legal and regulatory risks that could hit adoption, labeling and reputation. Article Title
• Negative Sentiment: Valuation and legal concerns: coverage warns FDA warnings and potential lawsuits are testing Novo’s high-growth valuation — a headwind for sentiment. Article Title
• Negative Sentiment: Analyst downgrades and weak guidance: Deutsche Bank cut its price target and Zacks moved to a “strong sell” after Novo’s cautious 2026 outlook and signs of slowing Ozempic/Wegovy growth. Those analyst moves are pressuring the stock. Article Title Article Title
• Negative Sentiment: Macro/technical risk: several analysts and technical reports argue the stock’s recent drop could accelerate if guidance-driven earnings disappointments continue, pointing to lower support levels. Article Title

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.